Strong Prospects for Fill-Finish Contract Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Strong Prospects for Fill-Finish Contract Manufacturing
A recent market analysis offers a promising outlook for contract fill-finish and lyophilization services.

The market for biopharmaceutical contract fill-and-finish services reached $1.2 billion in 2012, an increase of 33% over the past two years, according to an analysis by the market research firm High-Tech Business Decisions. This growth results from the underlying growth in the biopharmaceutical market, expansion of services offered by fill-and-finish contract manufacturing organizations and the greater use of contract manufacturing organizations by pharmaceutical and biotechnology companies (1). Contract manufacturing organizations with traditional aseptic, small-molecule filling capacity have expanded their capabilities to meet the filling challenges of temperature sensitive and fragile protein drugs. The biotechnology industry continues to use fill-and-finish contract manufacturers to provide expertise, filling capacity and lyophilization as they focus on drug development and API manufacturing.

The analysis notes that long-term prospects for biopharmaceutical fill-and-finish contractors remain strong with growth opportunities in new presentations that offer improved convenience for both patients and healthcare providers. Other growth opportunities include new services associated with special handling of niche products and smaller dosage volumes. As a result of these growth opportunities, this study projects the worldwide market for biopharmaceutical fill-and-finish contract manufacturing will continue to expand through 2017, reaching $1.6 billion.

"Biopharmaceutical products are becoming increasingly complex requiring special technologies and handling. Capacity utilization rates at contract manufacturing organizations have improved somewhat from two years ago," said William Downey, president of HighTech Business Decisions, in a High-Tech Business Decision release (1). "The investment in new fill capacity by contract manufacturing organizations will be modest over the coming years, thereby keeping industry utilization rates stable. New opportunities exist as the industry evolves to be more flexible with broader offerings and increased capabilities."

1. High-Tech Business Decisions, "Biopharmaceutical Fill-and-Finish Contract Manufacturing Study Shows Market Growth and New Opportunities," Press Release, Jan. 17, 2013.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here